Trade ResMed Inc - US - RMD
ResMed (RMD) is a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD) and other chronic diseases. SDB includes obstructive sleep apnoea (OSA), and other respiratory disorders that occur during sleep. The company’s products and solutions are designed to improve patient quality of life, reduce the impact of chronic disease and lower healthcare costs as global healthcare systems continue to drive a shift in care from hospitals to the home and lower cost settings. ResMed’s cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes and efficiencies for their customers. ResMed employs about 5,000 employees worldwide, operates in 100 countries and has manufacturing facilities in Australia, France, Singapore and the US. The ResMed share price is available at Capital.com.Latest shares articles

BAE Systems stock forecast: H1 results, guidance upgrade
BAE Systems is a UK defence and aerospace group listed in London. In August 2026, it secured a $149.8m US Navy award for work on the USS Boxer. Explore third-party BA. price targets and technical analysis. Past performance is not a reliable indicator of future results.
07:18, 16 October 2026

TAURON stock forecast: H1 earnings
TAURON is a Polish energy group. In the first half of 2026, revenue was broadly flat, while EBITDA and net profit fell amid higher CO2 allowance costs and coal consumption. Explore third-party analyst targets and technicals. Past performance is not a reliable indicator of future results.
12:04, 12 October 2026

Puma stock forecast: Anta stake deal cleared
Puma is a German sportswear company. Chinese regulators have cleared Anta Sports’ proposed acquisition of an approximately 29% stake, with completion expected before the end of 2026. Explore third-party PUM price targets. Past performance is not a reliable indicator of future results.
10:19, 12 October 2026

Dino Polska stock forecast: H1 sales growth slows
Dino Polska is a Polish grocery retailer. In H1 2026, revenue rose 12.5% year on year to 18.0bn PLN, while like-for-like sales growth slowed to 2.2%. Explore third-party DNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
08:27, 12 October 2026
Related News